Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2).

Autor:	Qaseem A; American College of Physicians, Philadelphia, Pennsylvania (A.Q.)., Yost J; American College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.)., Abraham GM; University of Massachusetts Medical School and Saint Vincent Hospital, Worcester, Massachusetts (G.M.A.)., Andrews R; University of Connecticut, Mansfield, Connecticut (R.A.)., Jokela JA; Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois (J.A.J.)., Miller MC; Penn Medicine, Philadelphia, Pennsylvania (M.C.M.)., Humphrey LL; Portland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (L.L.H.)., Dunn A, Haeme R, Lee R, Saini SD, Tschanz CMP, Etxeandia-Ikobaltzeta I, Harrod C, Shamliyan T, Umana K
Jazyk:	angličtina
Zdroj:	Annals of internal medicine [Ann Intern Med] 2023 Oct; Vol. 176 (10), pp. 1396-1404. Date of Electronic Publication: 2023 Sep 19.
DOI:	10.7326/M23-1636
Abstrakt:	Description: Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant. Methods: The Population Health and Medical Science Committee (formerly the Scientific Medical Policy Committee) developed this version of the living, rapid practice points on the basis of a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems (Danube University Krems). This topic will be maintained as living and rapid by continually monitoring and assessing the impact of new evidence. Practice Point 1: Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Practice Point 2: Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Practice Point 3: Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Practice Point 4: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Competing Interests: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-1636. All financial and intellectual disclosures of interest were declared, and potential conflicts were discussed and managed. Drs. Akl, Kansagara, Mackey, Obley, and Wilt were recused from authorship and voting due to moderate-level conflicts of interest (recently authored relevant publications). A record of disclosures of interest and management of conflicts is kept for each PHMSC meeting and conference call and can be viewed at www.acponline.org/about-acp/who-we-are/leadership/boards-committees-councils/population-health-and-medical-science-committee/disclosure-of-interests-and-conflict-of-interest-management-summary-for-scientific-medical-policy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu